Enzyme substrate recognition in oxygen sensing: how the HIF trap snaps
- PMID: 17990984
- PMCID: PMC2267343
- DOI: 10.1042/BJ20071306
Enzyme substrate recognition in oxygen sensing: how the HIF trap snaps
Abstract
The transcriptional activator HIF (hypoxia-inducible factor) is a focal point of biomedical research because many situations in physiology and in pathology coincide with hypoxia. The effects of HIF activation may be a facet of normal growth, as in embryonic development, they may counterbalance a disease, as seen in the stimulation of erythropoiesis in anaemia, and they may be part of the pathological processes, as exemplified by tumour angiogenesis. The oxygen-sensitive alpha-subunits of HIF are primarily regulated by the enzymatic hydroxylation that induces rapid proteasomal degradation. The HIFalpha hydroxylases belong to a superfamily of dioxygenases that require the co-substrates oxygen and 2-oxoglutarate as well as the cofactors Fe2+ and ascorbate. The regulation of enzyme turnover by the concentration of the cosubstrate oxygen constitutes the interface between tissue oxygen level and the activity of HIF. The HIFalpha prolyl hydroxylases, termed PHDs/EGLNs (prolyl hydroxylase domain proteins/EGL nine homologues), bind to a conserved Leu-Xaa-Xaa-Leu-Ala-Pro motif present in all substrates identified so far. This recognition motif is present twice in HIF1alpha, which gives rise to a NODD [N-terminal ODD (oxygen-dependent degradation domain)] containing Pro402 of HIF1alpha and a CODD (C-terminal ODD) where Pro564 is hydroxylated. PHD1/EGLN2 and PHD2/EGLN1 hydroxylate both ODDs with higher activity towards CODD, whereas PHD3/EGLN3 is specific for CODD. The reason for this behaviour has been unclear. In this issue of the Biochemical Journal, Villar and colleagues demonstrate that distinct PHD/EGLN domains, that are remote from the catalytic site, function in substrate discrimination. This elegant study improves our understanding of the interaction of the oxygen-sensing PHDs/EGLNs with their substrates, which include, but are not limited to, the HIFalpha proteins.
Comment on
-
Identification of a region on hypoxia-inducible-factor prolyl 4-hydroxylases that determines their specificity for the oxygen degradation domains.Biochem J. 2007 Dec 1;408(2):231-40. doi: 10.1042/BJ20071052. Biochem J. 2007. PMID: 17725546 Free PMC article.
Similar articles
-
Identification of a region on hypoxia-inducible-factor prolyl 4-hydroxylases that determines their specificity for the oxygen degradation domains.Biochem J. 2007 Dec 1;408(2):231-40. doi: 10.1042/BJ20071052. Biochem J. 2007. PMID: 17725546 Free PMC article.
-
Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2α to prolyl hydroxylase domain 2.Proteins. 2023 Nov;91(11):1510-1524. doi: 10.1002/prot.26541. Epub 2023 Jul 14. Proteins. 2023. PMID: 37449559 Free PMC article.
-
Analysis of HIF-prolyl hydroxylases binding to substrates.Biochem Biophys Res Commun. 2006 Dec 15;351(2):313-20. doi: 10.1016/j.bbrc.2006.09.170. Epub 2006 Oct 16. Biochem Biophys Res Commun. 2006. PMID: 17069766
-
HIF hydroxylation and cellular oxygen sensing.Biol Chem. 2004 Mar-Apr;385(3-4):223-30. doi: 10.1515/BC.2004.016. Biol Chem. 2004. PMID: 15134335 Review.
-
The non-canonical functions of HIF prolyl hydroxylases and their dual roles in cancer.Int J Biochem Cell Biol. 2021 Jun;135:105982. doi: 10.1016/j.biocel.2021.105982. Epub 2021 Apr 21. Int J Biochem Cell Biol. 2021. PMID: 33894356 Review.
Cited by
-
Vitamin C: update on physiology and pharmacology.Br J Pharmacol. 2009 Aug;157(7):1097-110. doi: 10.1111/j.1476-5381.2009.00282.x. Epub 2009 Jun 5. Br J Pharmacol. 2009. PMID: 19508394 Free PMC article. Review.
-
A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients.Mol Cancer. 2010 Jul 12;9:185. doi: 10.1186/1476-4598-9-185. Mol Cancer. 2010. PMID: 20624283 Free PMC article.
-
Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells.Genome Res. 2010 Aug;20(8):1064-83. doi: 10.1101/gr.104935.110. Epub 2010 Jun 21. Genome Res. 2010. PMID: 20566737 Free PMC article.
-
DSIR: assessing the design of highly potent siRNA by testing a set of cancer-relevant target genes.PLoS One. 2012;7(10):e48057. doi: 10.1371/journal.pone.0048057. Epub 2012 Oct 30. PLoS One. 2012. PMID: 23118925 Free PMC article.
References
-
- Schofield C. J., Ratcliffe P. J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004;5:343–354. - PubMed
-
- Vogelstein B., Kinzler K. W. Cancer genes and the pathways they control. Nat. Med. 2004;10:789–799. - PubMed
-
- Creighton-Gutteridge M., Cardellina J. H., Stephen A. G., Rapisarda A., Uranchimeg B., Hite K., Denny W. A., Shoemaker R. H., Melillo G. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1α protein accumulation by NSC 644221. Clin. Cancer Res. 2007;13:1010–1018. - PubMed
-
- Astellas Pharma Inc. Tokyo: Astellas Pharma Inc; 2007. Adverse event of FG-2216 for the treatment of anemia (pamphlet; also available at www.astellas.com/global/about/news/2007/pdf/070507_eg.pdf)
-
- Makino Y., Kanopka A., Wilson W. J., Tanaka H., Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3α locus. J. Biol. Chem. 2002;277:32405–32408. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources